A comparison of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios in schizophrenia and bipolar disorder patients – a retrospective file review

Özdin, Selçuk; Sarısoy, Gökhan; Böke, Ömer

doi:10.1080/08039488.2017.1340517

Cited by 107 publications

(85 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[31][32][33] Immunemediated alterations in serotoninergic and glutamatergic systems may result in mood and cognitive symptoms while inflammation-induced modifications of dopaminergic Open access systems may result in motivational deficits found across different psychiatric disorders. 34 In contrast to previous reports, [15][16][17] we did not find NLR to differ between bipolar affective disorder and schizophrenia, between bipolar affective disorder or depression, or between depression and AD after correcting for covariates. This contradiction in findings may be attributed to the larger sample size in our study.…”

Section: Discussioncontrasting

confidence: 99%

“…5 True transdiagnostic studies are rare with only three studies to date comparing NLR between psychiatric diagnoses. [15][16][17] Of the NLR studies comparing different psychiatric diagnoses, Ozdin et al reported that patients with schizophrenia, experiencing a psychotic episode, had higher NLR than patients with manic-phase BD, suggesting that there are detectable differences in NLR across diagnosis and symptomatology. 15 Mazza et al found that patients with manic-phase BD had higher NLR than patients with major depressive disorder (MDD).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil–lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records

Brinn

Stone

2020

BMJ Open

View full text Add to dashboard Cite

ObjectivesThe main objective of this study was to compare neutrophil–lymphocyte ratio (NLR), a marker of systemic inflammation, between patients diagnosed with International Classification of Diseases 10th Revision (ICD-10) psychiatric disorders and control participants.DesignA cross-sectional methodology was employed to retrospectively analyse electronic health records and records derived from a national health survey.SettingA secondary mental healthcare service consisting of four boroughs in South London.ParticipantsA diverse sample of 13 888 psychiatric patients extracted from South London and Maudsley electronic health records database and 3920 control participants extracted from National Health and Nutrition Survey (2015–2016) were included in the study.Primary and secondary outcome measuresPrimary: NLR levels in patients with mental health diagnoses, NLR between patients with different mental health diagnoses. Secondary: relationship of NLR to length of hospitalisation and to mortality.ResultsNLR was elevated compared with controls in patients with diagnoses including dementia, alcohol dependence, schizophrenia, bipolar affective disorder, depression, non-phobic anxiety disorders and mild mental retardation (p<0.05). NLR also correlated with age, antipsychotic use and hypnotic use. NLR was found to be higher in individuals of ‘white’ ethnicity and lower in individuals of ‘black’ ethnicity. Elevated NLR was associated with increased mortality (β=0.103, p=2.9e−08) but not with hospital admissions or face-to-face contacts.ConclusionsElevated NLR may reflect a transdiagnostic pathological process occurring in a subpopulation of psychiatric patients. NLR may be useful to identify and stratify patients who could benefit from adjunctive anti-inflammatory treatment.

show abstract

Section: Discussioncontrasting

confidence: 99%

mentioning

confidence: 99%

Neutrophil–lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records

Brinn

Stone

2020

BMJ Open

View full text Add to dashboard Cite

show abstract

“…However, less is known on the role of MPO in individuals without symptomatic CVD, but epidemiologic studies demonstrate that MPO may predict future risk of coronary artery disease ( 50 ). Furthermore, elevated neutrophil counts have been reported in BD and SCZ ( 51 – 53 ) and based on the increased MPO levels observed in our study, it is tempting to speculate that abnormalities in neutrophil activation could represent an early event in the progression of CVD in patients with psychotic disorders. The stronger association with the TC/HDL compared to the TG/HDL, could suggest that the enhanced MPO is more directly linked to atherogenesis and not only a marker of this process.…”

Section: Discussionsupporting

confidence: 57%

Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders

et al. 2020

View full text Add to dashboard Cite

Results: A markedly higher proportion (26%-31%) of patients had increased TC/HDL and TG/HDL ratios compared with HC. Plasma levels of high-sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO) were higher (p<0.05, p<0.001) in patients with psychotic disorders than in HC, and hs-CRP and MPO were independently associated with atherogenic lipid ratios in the multivariable analyses. Conclusions: Our findings suggest that low-grade inflammation and abnormal neutrophil activation may cause increased CVD risk in patients with psychotic disorders. These mechanisms should be further examined to determine the potential for development of novel risk evaluation strategies.

show abstract

“…Neutrophil-lymphocyte ratio (NLR) have been used as an indicator of inflammation. An elevation of NLR and neutrophils, and lower levels of lymphocytes were found in patients with SZ 44,45 . NLR is a strong predictor of systemic inflammation; NLR high values may be involved in the pathophysiology of SZ (inflammatory hypothesis), and also may be correlated with cognitive impairment 46,47 .…”

Section: Resultsmentioning

confidence: 93%

Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia

Rodrigues-Amorím

Rivera-Baltanás

Vallejo-Curto

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Schizophrenia is a progressive disorder characterized by multiple psychotic relapses. After every relapse, patients may not fully recover, and this may lead to a progressive loss of functionality. Pharmacological treatment represents a key factor to minimize the biological, psychological and psychosocial impact of the disorder. The number of relapses and the duration of psychotic episodes induce a potential neuronal damage and subsequently, neurodegenerative processes. Thus, a comparative study was performed, including forty healthy controls and forty-two SZ patients divided into first-episode psychosis (FEP) and chronic SZ (CSZ) subgroups, where the CSZ sub group was subdivided by antipsychotic treatment. In order to measure the potential neuronal damage, plasma levels of β-III tubulin, neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) were performed. The results revealed that the levels of these proteins were increased in the SZ group compared to the control group (P < 0.05). Moreover, multiple comparison analysis showed highly significant levels of β-III tubulin (P = 0.0002), Nf-L (P = 0.0403) and GFAP (P < 0.015) in the subgroup of CSZ clozapine-treated. In conclusion, β-III tubulin, Nf-L and GFAP proteins may be potential biomarkers of neurodegeneration and progression in SZ. Schizophrenia (SZ) is a complex, severe and heterogeneous disorder. Unfortunately, its aetiology and pathophysiology remains unclear 1. Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women, and its deteriorating course makes SZ the most disabling psychiatric disorder 2. SZ has been explained both by neurodevelopmental and neurodegenerative models, which include neuronal damage and grey matter abnormalities 3,4. Both models may be complementary, and four stages can be proposed in the course of SZ 5-11 (Fig. 1). Moreover, the duration of untreated psychosis (DUP) is a critical period during schizophrenia course. Accumulating evidence suggests that a longer DUP is associated with clinical deterioration, including increased symptoms severity, cognitive and functioning declines, and poorer response to antipsychotics 12,13. SZ patients treated immediately after the FEP will suffer less cognitive impairment and disability 14-17. Cognitive deficits are considered part of the core symptoms of SZ 18. Both abnormalities in prenatal life and in the early childhood neurodevelopment are associated with SZ, and they may explain the early cognitive decline that characterizes this disorder 8,19. Pathological neurodevelopment described in SZ patients may be explained

show abstract

A comparison of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios in schizophrenia and bipolar disorder patients – a retrospective file review

Cited by 107 publications

References 18 publications

Neutrophil–lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records

Neutrophil–lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records

Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders

Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia

Contact Info

Product

Resources

About